Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18773410 | 0.83 | FDPS (0.43) | FDPSKCNH2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL19954424 | 0.81 | KCNH3 (0.31) | CCR4RAB9A | |
| SCHEMBL19383796 | 0.80 | CYP3A4 (0.41) | FDPSKCNH2CYP3A4CYP1A2CYP2D6 | |
| SCHEMBL2476938 | 0.80 | KCNH2 (0.41) | ESR1KCNH2CCR4RAB9ANOS1 | |
| SCHEMBL21157383 | 0.78 | FDPS (0.35) | LOXL2FDPSESR1CYP3A4ALDH1A1 | |
| SCHEMBL18994401 | 0.78 | HTT (0.35) | KCNH2CCR4ALDH1A1HSD17B10RAB9A | |
| SCHEMBL21533982 | 0.77 | KCNH2 (0.38) | KCNH2CCR4NOS1NOS2HRH4 | |
| SCHEMBL21156480 | 0.75 | CYP11B1 (0.36) | LOXL2FDPSESR1CYP3A4CYP17A1 | |
| SCHEMBL73475 | 0.75 | ESR1 (0.52) | LOXL2FDPSESR1CYP3A4CYP17A1 | |
| SCHEMBL18675305 | 0.74 | ESR1 (0.38) | FDPSESR1CYP3A4CYP17A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SITEONE THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230212140-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-07-06 | — | — | US | disclosed |
| US-11643403-B2 | GLP-1 receptor agonist and use thereof | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-05-09 | — | — | US | disclosed |
| US-20230013143-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013143-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GPR119 | LOXL2 2498/4885FDPS 3201/4885ESR1 928/4885 |
| US-20230212140-A1 | GLP-1 RECEPTOR AGONIST AND USE THEREOF | GLP1R, GIPR, GPR119 | LOXL2 2498/4885FDPS 3201/4885ESR1 928/4885 |
| US-11643403-B2 | GLP-1 receptor agonist and use thereof | GLP1R, GIPR, GPR119 | LOXL2 2498/4885FDPS 3201/4885ESR1 928/4885 |
| US-20230339958-A1 | NON-HYDRATED KETONE INHIBITORS OF NAV1.7 FOR THE TREATMENT OF PAIN | SCN7A, SCN10A, HCN3 | LOXL2 4545/4885FDPS 2810/4885ESR1 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.